Browse Category

Pharmaceuticals News 16 January 2026 - 17 January 2026

Eli Lilly stock price in focus as FDA slips obesity pill deadline — what to watch in LLY next week

Eli Lilly stock price in focus as FDA slips obesity pill deadline — what to watch in LLY next week

Eli Lilly shares rose 0.5% to $1,038.40 Friday as the FDA set April 10 as the new target date for a decision on its experimental weight-loss pill. The agency delayed review timelines for several drugs, including Lilly’s, under its fast-track program. Novo Nordisk’s new Wegovy pill saw about 3,071 U.S. prescriptions in its first four days, according to IQVIA data.
Novo Nordisk stock jumps on Wegovy pill scripts and UK high-dose nod — what to watch next week

Novo Nordisk stock jumps on Wegovy pill scripts and UK high-dose nod — what to watch next week

Novo Nordisk shares surged 6.5% in Copenhagen and 9.1% in New York after early U.S. prescription data showed 3,071 Wegovy pill scripts filled in four days. Britain approved a higher maximum dose of Wegovy for obesity patients. A Texas compounding pharmacy sued Novo and Eli Lilly over alleged market dominance. Novo called the lawsuit “without merit.”
GSK stock slips into the weekend as insider dividend reinvestment filings land; eyes on Feb. 4 results

GSK stock slips into the weekend as insider dividend reinvestment filings land; eyes on Feb. 4 results

GSK shares fell 1.7% to 1,817 pence in London Friday, extending a three-day slide and closing 11.7% below their December peak. Trading volume surged to 12.6 million shares. Filings showed senior executives reinvested dividends into shares and U.S. ADSs. Investors are awaiting GSK’s full-year results and U.S. drug-approval updates in early February.
Merck stock price slips as FDA fast-track doubts surface before MRK earnings

Merck stock price slips as FDA fast-track doubts surface before MRK earnings

Merck & Co shares fell 1.9% to $108.83 Friday after a Reuters report highlighted industry concerns over the FDA’s new fast-track drug approval program. Internal FDA documents show some drug reviews have been delayed due to safety and effectiveness worries, including a patient death linked to Sanofi’s Tzield. The S&P 500 healthcare sector dropped 0.8% amid broader market weakness. Only one drug has been approved under the program so far.
Eli Lilly stock: FDA pushes orforglipron decision to April 10 as lawsuit adds another overhang

Eli Lilly stock: FDA pushes orforglipron decision to April 10 as lawsuit adds another overhang

Eli Lilly shares rose 0.5% in after-hours trading after the FDA delayed its decision on the company’s obesity drug orforglipron to April 10. Lilly and Novo Nordisk face a lawsuit from Texas-based Strive Specialties, which alleges both companies restricted access to cheaper compounded versions of GLP-1 drugs. Lilly also disclosed a 10% stake in Aktis Oncology.
Merck stock slips as FDA fast-track questions build and earnings near

Merck stock slips as FDA fast-track questions build and earnings near

Merck shares fell 1.2% to $109.65 Friday, underperforming the market as investors reacted to renewed scrutiny of the FDA’s expedited drug review program. The FDA delayed reviews of two drugs in the program after safety concerns, including a reported patient death. Merck is developing two drugs under this program and plans to report earnings on Feb. 3. About 7.6 million shares traded by the afternoon.
AbbVie stock slides on mixed lymphoma trial readout as investors eye the next catalyst

AbbVie stock slides on mixed lymphoma trial readout as investors eye the next catalyst

AbbVie shares fell 1.1% to $214.35 Friday after its lymphoma drug epcoritamab met a key trial goal but failed to show a statistically significant overall survival benefit. The company said it will consult regulators on next steps. AbbVie also outlined plans to expand into obesity drugs and will report earnings Feb. 4. U.S. markets close Monday for Martin Luther King Jr. Day.
PainReform PRFX stock jumps in premarket after company rebrands as PRF Technologies

PainReform PRFX stock jumps in premarket after company rebrands as PRF Technologies

PainReform shares rose about 13% in premarket trading after the company announced it has rebranded as PRF Technologies Ltd, keeping its Nasdaq ticker PRFX. The firm said it will expand beyond pain therapy into drug delivery and solar analytics. The announcement was filed with the SEC on Thursday. PRF Technologies continues to advance its PRF-110 pain treatment and LayerBio’s OcuRing-K ocular therapy.
Eli Lilly stock slides premarket after FDA sets April 10 target for weight-loss pill decision, GLP-1 lawsuit filed

Eli Lilly stock slides premarket after FDA sets April 10 target for weight-loss pill decision, GLP-1 lawsuit filed

Eli Lilly shares fell 3.8% premarket to $1,033 after FDA documents set an April 10 decision date for its weight-loss pill under a fast-track program. Strive Specialties sued Lilly and Novo Nordisk in Texas, alleging efforts to block cheaper compounded GLP-1 drugs. Novo Nordisk shares dropped 3%. Investors await further FDA guidance and Lilly’s Feb. 4 earnings call.
1 12 13 14 15 16 56

Stock Market Today

No $2,000 IRS stimulus check is coming in February 2026 — but Trump’s tariff-check talk keeps the rumors alive

No $2,000 IRS stimulus check is coming in February 2026 — but Trump’s tariff-check talk keeps the rumors alive

7 February 2026
Washington, Feb 7, 2026, 07:38 (EST) The IRS has not announced any new federal stimulus payments for February 2026, and Congress has not authorized another round of checks, Fox 5 DC reported. Online posts pushing $2,000 “tariff dividend” checks or other direct deposits have continued into 2026, sometimes mixing in state programs such as Alaska’s Permanent Fund Dividend, the report said. (fox5dc.com) The timing matters because tax filing season tends to put millions of people in “money-watching” mode. Refunds, credits and routine deposits hit bank accounts, and scammers try to ride the noise. President Donald Trump’s own comments have added
Go toTop